Home
January 2010 February 2010 March 2010
Su Mo Tu We Th Fr Sa
Week 5 1 2 3 4 5 6
Week 6 7 8 9 10 11 12 13
Week 7 14 15 16 17 18 19 20
Week 8 21 22 23 24 25 26 27
Week 9 28



GU Cancers Symposium - ASCO ASTRO SUO - 2008 - Preliminary Phase II Results of Abiraterone Acetate in Patients with Castration-resistant metastatic Prostate Cancer after Failure of Docetaxel-based Chemotherapy

SAN FRANCISCO, CA (UroToday.com) - Dr. Danila, spoke about abiraterone acetate (AA), an oral and irreversible inhibitor of CYP17 that decreases testosterone and DHT levels to undetectable. The study presented sought to determine the proportion of patients achieving a PSA decline of >50% and to assess toxicity.

Login to read more...

Written by Christopher P. Evans, MD, a Contributing Editor with UroToday.

Member's Section

Login

Sign Up

Quick Search